World Health Organisation (WHO) has issued an emergency use listing for Serum Institute of India’s manufactured Covovax. The move will help expand the basket of WHO-validated vaccines against the SARS-CoV-2 virus. In a statement, WHO said, the decision will give a much-needed boost to ongoing efforts to vaccinate more people in lower-income countries.
The Serum Institute of India (SII) is producing Covovax under licence from Novavax and is part of the COVAX facility portfolio. Taking to Twitter, SII CEO Adar Poonawalla said, this is yet another milestone in our fight against Covid-19. He said, Covovax is now WHO approved for emergency use, showing excellent safety and efficacy.
